GSK faces RSV vaccine threat from rival Pfizer
Drug Discovery World
JUNE 14, 2023
An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData. It is currently the only vaccine candidate in late-stage development that targets multiple patient segments.”
Let's personalize your content